

</p>

UNITED STATES

</p><p>SECURITIES AND EXCHANGE COMMISSION

</p><p>Washington, D.C. 20549</p><p>SCHEDULE 13D</p><p>Under the Securities Exchange Act of 1934</p><p>(Amendment No. 2)\*</p><p>iBio, Inc.</p><p>(Name of Issuer)</p><p>Common Stock, par value \$.001</p><p>(Title of Class of Securities)</p><p>45107K102</p><p>(CUSIP Number)</p><p>Carl DeSantis</p><p>c/o CDS International Holdings, Inc.</p><p>3299 NW 2nd Ave</p><p>Boca Raton, FL 33431</p><p>(561) 705-0394</p><p>(Name, Address and Telephone Number of Person)</p><p>Authorized to Receive Notices and Communications)</p><p>Copy to:</p><p>CDS International Holdings, Inc.</p><p>Attn: William Milmoe</p><p>3299 NW 2nd Ave</p><p>Boca Raton, FL 33431</p>

</p>  
    September 29, 2014  
</p>  
<p>  
    (Date of Event which Requires Filing of this Statement)  
</p>  
<p>  
    If the filing person has previously filed a statement on Schedule  
</p>  
<p>  
    13G to report the acquisition that is the subject of this  
</p>  
<p>  
    Schedule 13D, and is filing this schedule because of 240.13d-1(e),  
</p>  
<p>  
    240.13d-1(f) or 240.13d-1(g), check the following box.  
</p>  
<p>  
    Note: Schedules filed in paper format shall include a signed  
</p>  
<p>  
    original and five copies of the schedule,  
</p>  
<p>  
    including all exhibits. See 240.13d-7 for other parties  
</p>  
<p>  
    to whom copies are to be sent.  
</p>  
<p>  
    (Continued on following pages)  
</p>  
<p>  
    (Page 1 of 7 Pages)  
</p>  
<p>  
    CUSIP No. 45107K102  
</p>  
<p>  
    13D  
</p>  
<p>  
    Page 2 of 7 Pages  
</p>  
<p>  
    1.  
</p>  
<p>  
    NAME OF REPORTING PERSON  
</p>  
<p>  
    Carl DeSantis  
</p>  
<p>  
    2.  
</p>  
<p>  
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
</p>  
<p>  
    (see instructions)  
</p>  
<p>  
    (a) ?  
</p>  
<p>  
    (b) ?  
</p>  
<p>  
    3.  
</p>  
<p>

SEC USE ONLY

</p>

<p>

4.

</p>

<p>

SOURCE OF FUNDS (see instructions)

</p>

<p>

00

</p>

<p>

5.

</p>

<p>

CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED

PURSUANT TO ITEMS 2(d) or 2(e) ?

</p>

<p>

6.

</p>

<p>

CITIZENSHIP OR PLACE OF ORGANIZATION

</p>

<p>

United States

</p>

<p>

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

</p>

<p>

7.

</p>

<p>

SOLE VOTING POWER

</p>

<p>

6,125

</p>

<p>

8.

</p>

<p>

SHARED VOTING POWER

</p>

<p>

5,745,018

</p>

<p>

9.

</p>

<p>

SOLE DISPOSITIVE POWER

</p>

<p>

6,125

</p>

<p>

10.

</p>

<p>

SHARED DISPOSITIVE POWER

</p>

<p>

5,745,018

</p>

<p>

11.

</p>

<p>

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

</p>

<p>

5, 751, 143  
</p>  
<p>  
12.  
</p>  
<p>  
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES  
</p>  
<p>  
(see instructions) ?  
</p>  
<p>  
13.  
</p>  
<p>  
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
</p>  
<p>  
8.76%  
</p>  
<p>  
14.  
</p>  
<p>  
TYPE OF REPORTING PERSON (see instructions)  
</p>  
<p>  
IN  
</p>  
<p>  
\_\_\_\_\_  
</p>  
<p>  
CUSIP No. 45107K102  
</p>  
<p>  
13D  
</p>  
<p>  
Page 3 of 7 Pages  
</p>  
<p>  
1.  
</p>  
<p>  
NAME OF REPORTING PERSON  
</p>  
<p>  
DeSanitis Revocable Trust  
</p>  
<p>  
2.  
</p>  
<p>  
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
</p>  
<p>  
(see instructions)  
</p>  
<p>  
(a) ?  
</p>  
<p>  
(b) ?  
</p>  
<p>  
3.  
</p>  
<p>  
SEC USE ONLY  
</p>  
<p>  
4.  
</p>

</p>

<p> SOURCE OF FUNDS (see instructions)</p>

</p>

<p> 00</p>

<p> 5.</p>

</p>

<p> CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS</p>

</p>

<p> REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ?</p>

</p>

<p> 6.</p>

</p>

<p> CITIZENSHIP OR PLACE OF ORGANIZATION</p>

</p>

<p> Florida</p>

</p>

<p> NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH</p>

</p>

<p> 7.</p>

</p>

<p> SOLE VOTING POWER</p>

</p>

<p> 0</p>

</p>

<p> 8.</p>

</p>

<p> SHARED VOTING POWER</p>

</p>

<p> 2,947,749</p>

</p>

<p> 9.</p>

</p>

<p> SOLE DISPOSITIVE POWER</p>

</p>

<p> 0</p>

</p>

<p> 10.</p>

</p>

<p> SHARED DISPOSITIVE POWER</p>

</p>

<p> 2,947,749</p>

</p>

<p> 11.</p>

</p>

<p> AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</p>

</p>

<p> 2,947,749</p>

</p>

<p> 12.  
</p>  
<p> CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)  
</p>  
<p> EXCLUDES CERTAIN SHARES (see instructions) ?  
</p>  
<p> 13.  
</p>  
<p> PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)  
</p>  
<p> 4.49%  
</p>  
<p> 14.  
</p>  
<p> TYPE OF REPORTING PERSON (see instructions)  
</p>  
<p> OO  
</p>  
<p> CUSIP No. 45107K102  
</p>  
<p> 13D  
</p>  
<p> Page 4 of 7 Pages  
</p>  
<p> 1.  
</p>  
<p> NAME OF REPORTING PERSON  
</p>  
<p> CD Financial, LLC  
</p>  
<p> 2.  
</p>  
<p> CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
</p>  
<p> (see instructions)  
</p>  
<p> (a) ?  
</p>  
<p> (b) ?  
</p>  
<p> 3.  
</p>  
<p> SEC USE ONLY  
</p>  
<p> 4.  
</p>  
<p> SOURCE OF FUNDS (see instructions)  
</p>  
<p>

00  
</p>  
<p>  
5.  
</p>  
<p>  
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS  
</p>  
<p>  
2 (d) or 2 (e) ?  
</p>  
<p>  
6.  
</p>  
<p>  
CITIZENSHIP OR PLACE OF ORGANIZATION  
</p>  
<p>  
Florida  
</p>  
<p>  
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  
</p>  
<p>  
7.  
</p>  
<p>  
SOLE VOTING POWER  
</p>  
<p>  
0  
</p>  
<p>  
8.  
</p>  
<p>  
SHARED VOTING POWER  
</p>  
<p>  
1,530,563  
</p>  
<p>  
9.  
</p>  
<p>  
SOLE DISPOSITIVE POWER  
</p>  
<p>  
0  
</p>  
<p>  
10.  
</p>  
<p>  
SHARED DISPOSITIVE POWER  
</p>  
<p>  
1,530,563  
</p>  
<p>  
11.  
</p>  
<p>  
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
</p>  
<p>  
1,530,563  
</p>  
<p>  
12.  
</p>  
<p>  
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)

</p>

<p> EXCLUDES CERTAIN SHARES (see instructions) ?

</p>

<p> 13.

</p>

<p> PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

</p>

<p> 2.33%

</p>

<p> 14.

</p>

<p> TYPE OF REPORTING PERSON (see instructions)

</p>

<p> OO

</p>

<p> CUSIP No. 45107K102

</p>

<p> 13D

</p>

<p> Page 5 of 7 Pages

</p>

<p> Item 1. Security and Issuer.

</p>

<p> This Amendment No. 2 updates and amends certain information initially

</p>

<p> reported in the Statement of Beneficial Ownership on Schedule 13D filed

</p>

<p> with the Securities and Exchange Commission on June 13, 2013, as amended

</p>

<p> by Amendment No. 1 dated August 13, 2013, by Carl DeSantis, CD Financial,

</p>

<p> LLC and the DeSantis Revocable Trust (the "Schedule 13D") in connection

</p>

<p> with the ownership of shares of common stock, par value \$0.001 per share

</p>

<p> (the "Common Stock") of iBio, Inc., a Delaware corporation (the "Issuer"),

</p>

<p> by Carl DeSantis, the DeSantis Revocable Trust and CD Financial, LLC

</p>

<p> ("CD Financial"). Unless otherwise indicated, all capitalized terms used

</p>

<p> but not defined herein shall have the same meaning ascribed to them in

</p>

<p> the Schedule 13D.

</p>

<p> Item 3. Source or Amount of Funds or Other Consideration.

</p>

<p> Item 3 of the Schedule 13D is hereby amended and restated

</p>

<p> in its entirety as follows:

</p>

<p> All of the securities reported on this Statement owned by Carl

</p>

<p> DeSantis and CD Financial, LLC were acquired as a result of the

</p>

<p> spin-off (the "Spin-Off") of the Issuer from Integrated BioPharma,

</p>

<p> except for 63,100 shares of Common Stock acquired by CD Financial

</p>

<p> subsequent to the Spin-Off in August 2010 in a private transaction.

</p>

<p> The shares of the Issuer were distributed to all of the

</p>

<p> stockholders of record of Integrated BioPharma as of August 12, 2008.

</p>

<p> Integrated BioPharma's stockholders received one Share of the

</p>

<p> Issuer's Common Stock for every one share of Integrated BioPharma

</p>

<p> common stock owned by them at the close of business on August 12, 2008.

</p>

<p> The date of distribution of the Issuers Common Stock was August 18, 2008.

</p>

<p> 1,834,489 shares of the securities reported on this Statement

</p>

<p> owned by the DeSantis Revocable Trust were acquired by DeSantis Revocable

</p>

<p> Trust from CDS Group Holdings, LLC ("CDS Group") in a private transaction

</p>

<p> in August 2008. CDS Group acquired such securities as a result of the

</p>

<p> Spin-Off. 1,113,260 shares of the securities reported on this Statement

</p>

<p> owned by the DeSantis Revocable Trust were acquired by DeSantis Revocable

</p>

<p> Trust in July 2013 in a private transaction for a purchase price of

</p>

<p> \$0.52 per share.

</p>

<p> Except as provided in the preceding paragraph, no funds or other

</p>

<p> consideration was used by any of the Reporting Persons to acquire the

</p>

<p> shares subject hereof, and no funds or other consideration were

</p>

<p> borrowed or otherwise obtained for the purpose of acquiring, holding,

</p>

<p>

trading, or voting the shares subject hereto.

</p>

<p> Item 5. Interest in Securities of the Issuer.

</p>

<p> Item 5 of the Schedule 13D is hereby amended and restated in

</p>

<p> its entirety as follows:

</p>

<p> (a) The Reporting Persons may be deemed to have beneficial

</p>

<p> ownership of 5,751,143 shares of Common Stock of the Issuer, representing

</p>

<p> approximately 8.76% of the Issuer's outstanding shares of Common Stock

</p>

<p> (the percentage of shares owned being based upon 65,642,095 shares

</p>

<p> outstanding on May 15, 2014 as

</p>

<p> reported on the Issuer's Quarterly Report on Form 10-Q for the quarter

</p>

<p> ended March 31, 2014, filed with the Securities and Exchange Commission

</p>

<p> on May 15, 2014). The percentage of ownership reported above in this

</p>

<p> Item 5(a) was calculated in accordance with Rule 13d-3(d) (1) (i)

</p>

<p> promulgated under the Securities Exchange

</p>

<p> Act of 1934, as amended (the "Exchange Act").

</p>

<p> (b) Carl DeSantis holds sole voting and dispositive power

</p>

<p> with respect to, and directly beneficially owns in the aggregate,

</p>

<p> 6,125 shares of Common Stock. CD Financial owns 1,530,563 shares

</p>

<p> of Common Stock, of which Carl DeSantis may be deemed to be the

</p>

<p> indirect beneficial owner (as that term is defined under Rule 13d-3

</p>

<p> under the Exchange Act) by virtue of the fact that he has the

</p>

<p> power to make decisions at CD Financial. Carl DeSantis may

</p>

<p> CUSIP No. 45107K102

</p>

<p> 13D

</p>

<p> Page 6 of 7 Pages

</p>

<p>     additionally be deemed to share beneficial ownership as well as voting

</p>

<p>     and dispositive power with the DeSantis Revocable Trust with respect

</p>

<p>     to 2,947,749 shares of Common Stock as Carl DeSantis is the trustee of

</p>

<p>     the DeSantis

</p>

<p>     Revocable Trust. As a holder of greater than 10% of the outstanding

</p>

<p>     shares of Integrated BioPharma, Carl DeSantis may also be deemed to

</p>

<p>     share beneficial ownership of the 1,266,706 shares held by Integrated

</p>

<p>     BioPharma.

</p>

<p>     CD Financial holds shared voting and dispositive power with respect

</p>

<p>     to, and directly beneficially owns in the aggregate, 1,530,417 shares of

</p>

<p>     Common Stock. CD Financial may be deemed to share beneficial ownership as

</p>

<p>     well as voting and dispositive power with respect to such Common Stock with

</p>

<p>     Carl DeSantis who has the power to make decisions at CD Financial.

</p>

<p>     The DeSantis Revocable Trust holds shared voting and dispositive power

</p>

<p>     with respect to, and directly beneficially owns in the aggregate, 2,947,749

</p>

<p>     shares of Common Stock. The DeSantis Revocable Trust may be deemed to share

</p>

<p>     beneficial ownership as well as voting and dispositive power with respect to

</p>

<p>     such Common Stock with Carl DeSantis, who is the trustee of the DeSantis

</p>

<p>     Revocable Trust.

</p>

<p>     (c) Carl DeSantis and CD Financial have not effected any transaction

</p>

<p>     in the Common Stock of the Issuer directly owned by them in the

past sixty days.

</p>

<p>     The DeSantis Revocable Trust has effected the following transactions in the

</p>

<p>     Common Stock of the Issuer within the past sixty days:

</p>

<p>     (i) On September 15, 2014 the DeSantis Revocable Trust sold 53,130

</p>

<p> shares of Common Stock of the Issuer in a private sale for a sale price of \$0.60

</p>

<p> per share.

</p>

<p> (ii) On September 16, 2014 the DeSantis Revocable Trust sold 29,880

</p>

<p> shares of Common Stock of the Issuer in a private sale for a sale price of \$0.63

</p>

<p> per share.

</p>

<p> (iii) On September 17, 2014 the DeSantis Revocable Trust sold 55,700 shares of Common Stock of the Issuer in a private sale for a sale price of

</p>

<p> \$0.76 per share.

</p>

<p> (d) With the exception of the 1,266,706 shares held by Integrated BioPharma,

</p>

<p> of which Carl DeSantis may be deemed to share beneficial ownership, no person other

</p>

<p> than the Reporting Persons has the right to receive or the power to direct the receipt

</p>

<p> of dividends from, or the proceeds from the sale of, the Common Stock covered by

</p>

<p> this Statement.

</p>

<p> (e) Not applicable.

</p>

<p> CUSIP No. 45107K102

</p>

<p> 13D

</p>

<p> Page 7 of 7 Pages

</p>

<p> SIGNATURE

</p>

<p> After reasonable inquiry and to the best of my knowledge and belief, I certify

</p>

<p> that the information set forth in this statement is true, complete and correct.

</p>

<p> Dated: September 29, 2014

</p>

*/s/Carl DeSantis*  
</p>  
<p>  
    *Carl DeSantis, individually*  
</p>  
<p>  
    *DeSantis*  
</p>  
<p>  
    *Revocable Trust*  
</p>  
<p>  
    *Dated:*  
</p>  
<p>  
    *September 29, 2014*  
</p>  
<p>  
    *By: /s/Carl DeSantis*  
</p>  
<p>  
    *Name: Carl DeSantis*  
</p>  
<p>  
    *Title: Trustee*  
</p>  
<p>  
    *CD Financial, LLC*  
</p>  
<p>  
    *Dated:*  
</p>  
<p>  
    *September 29, 2014*  
</p>  
<p>  
    *By: /s/Carl DeSantis*  
</p>  
<p>  
    *Name: Carl DeSantis*  
</p>  
<p>  
    *Title: Manager*  
</p>